Skip to main content

Table 1 Demographic and disease characteristics of the psoriatic arthritis patient cohort at baseline

From: Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register

Characteristic

Complete psoriatic arthritis cohort (n = 566)

Etanercept (n = 316)

Infliximab (n = 162)

Adalimumab (n = 88)

P value

Demographic

     

   Age (years)

45.7 ± 11.1

45.8 ± 11.1

44.8 ± 11.0

47.0 ± 11.6

0.325

   Female

300 (53.0)

162 (51.3)

89 (54.9)

47 (53.4)

0.581

   Disease duration (years)

12.4 ± 8.7

12.8 ± 9.0

12.2 ± 8.0

11.4 ± 8.4

0.384

   Patients with other baseline co-morbidities

375 (62.9)

191 (57.4%)

117 (68.4%)

67 (72.8%)

0.111

Disease

     

   28-Tender joint count

13.4 ± 7.7

13.5 ± 7.6

14.1 ± 8.1

12.1 ± 7.1

0.346

   28-Swollen joint count

8.9 ± 6.1

8.8 ± 6.1

8.8 ± 6.4

9.7 ± 5.7

0.293

   Erythrocyte sedimentation rate (mm)

40.5 ± 29.0

39.4 ± 28.1

44.2 ± 31.4

37.7 ± 27.4

0.459

   C-reactive protein level (mg/dl)

39.3 ± 47.1

35.4 ± 41.8

47.8 ± 50.0

35.0 ± 56.6

0.787

   28-joint Disease Activity Score

6.4 ± 5.6

6.1 ± 1.2

7.3 ± 10.1

6.0 ± 1.0

0.464

   Health Assessment Questionnaire

1.9 (1.4 to 2.3)

1.8 (1.4 to 2.3)

2.0 (1.4 to 2.4)

1.8 (1.1 to 2.3)

0.581

  1. Data presented as the mean ± standard deviation, n (%) or median (interquartile range). P value tests for significant differences between the three anti-TNF cohorts.